Aurobindo Pharma Limited has officially announced the outcome of its Board Meeting held on April 6, 2026, primarily focusing on a significant share buyback proposal. The company intends to repurchase up to 54,23,728 equity shares, representing 0.93% of its total paid-up equity share capital. This strategic move is set at a buyback price of INR 1,475 per equity share, payable in cash.

The total aggregate amount for this buyback is capped at INR 800 Crores, which accounts for 3.93% and 2.62% of the company’s total paid-up equity capital and free reserves on a standalone and consolidated basis, respectively, as of March 31, 2025. The buyback will be executed through the “tender offer” route on a proportionate basis from all existing shareholders. To manage the process, the Board has established a dedicated Buyback Committee and fixed April 17, 2026, as the Record Date to determine eligible shareholders.

Aurobindo Pharma is a leading global pharmaceutical giant, manufacturing over 250 API products and maintaining a robust portfolio of 225+ product families. In 2025, the company continued its expansion in the biosimilars and specialty generics segments, bolstered by its flagship Penicillin-G facility in Kakinada. Recent updates include USFDA approvals for Everolimus Tablets and the launch of Pomalidomide Capsules in the US market. The firm operates 29 manufacturing facilities globally and serves over 150 markets.

For the quarter ended December 31, 2025 (Q3 FY25-26), the company reported a consolidated revenue of INR 8,646 Crores, marking an 8.4% increase compared to INR 7,979 Crores in the same period last year. Consolidated net profit rose by 7.6% to INR 910 Crores from INR 846 Crores year-on-year. Major investors in the company include top mutual funds like Mirae Asset Healthcare Fund and ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund.